Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

This study has been terminated.
(Because the conditional power was 0.083, the Data and Safety Monitoring Board recommended halting the study due to futility after the 1st interim analysis.)
Sponsor:
Information provided by (Responsible Party):
Xiaojun Huang, Peking University People's Hospital
ClinicalTrials.gov Identifier:
NCT01517347
First received: January 10, 2012
Last updated: October 20, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)